The ALEX study's final analysis shows that first-line alectinib significantly improves OS and duration of response in untreated advanced ALK+ NSCLC compared to crizotinib, reinforcing alectinib as the standard of care for these patients.

The monarchE trial reveals that adjuvant abemaciclib combined with endocrine therapy (ET) significantly enhances overall survival (OS) and invasive disease-free survival in patients with high-risk, hormone receptor-positive (HR+), HER2-negative early breast cancer, establishing this regimen as a new standard of care.

In the final OS analysis of the CheckMate 816 trial, neoadjuvant nivolumab + chemotherapy significantly improved OS in patients with resectable non-small cell lung cancer (NSCLC) compared to chemotherapy alone. With median OS not reached in the nivolumab group vs. 73.7 months in the chemotherapy group , these findings underscore the potential of this combination therapy as a new standard of care.

Osimertinib is a third-generation, orally administered epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) previously approved for the first-line treatment of EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC).1,2 Results from the phase 3 FLAURA trial showed that os

STUDY DESIGN Dostarlimab in conjunction with carboplatin-paclitaxel (CP) has previously been shown to significantly improve progression-free survival (PFS) and overall survival (OS) outcomes compared with CP alone in patients with primary advanced or recurrent endometrial cancer (EC).1 This has led

STUDY DESIGN Niraparib is a potent and highly selective poly-ADP ribose polymerase (PARP) inhibitor.1 PARP inhibitors have shown a trend of favorable overall survival (OS) in platinum-sensitive recurrent ovarian cancer (PSROC) in the maintenance setting.1 However, this OS benefit appears inconsiste

Thrombocytosis is frequently observed among cancer patients and can be attributed to increased platelet production.1 While the underlying pathophysiology has not been completely elucidated, it is believed that platelet activation is essential for tumor progression due to the release of several plate

STUDY DESIGN For over 2 decades, locally advanced cervical cancer (LACC) has been treated with external beam radiotherapy (EBRT) and concurrent chemotherapy, followed by brachytherapy.1 However, the toxicity associated with these treatments along with the burden of the disease itself have led to a

Progression-free survival (PFS) is often utilized as an indicator of the overall survival (OS) of patients with endometrial cancer (EC) to facilitate regulatory approval for novel medical treatments.1 Nevertheless, its role as a surrogate marker for the survival outcomes of EC patients remains contr

Although surgery remains the first-line treatment for patients with early-stage resectable non-small-cell lung cancer (NSCLC), recent evidence has shown that the incorporation of immunotherapy with immune checkpoint inhibitors, such as programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1), demonstrated benefits in the perioperative settings.¹ It is believed that the enhanced perioperative regimens, by combining the benefits of neoadjuvant and adjuvant immunotherapy, could further improve patients’ long-term clinical outcomes.¹